可溶性尿激酶纤溶酶原激活剂受体 (suPAR) 是尿激酶纤溶酶原激活剂受体的可溶性对应物，存在于循环系统中的各个水平。 suPAR 及其母体分子细胞表面 uPAR 表现出相似的结构和细胞外功能，促进纤溶、细胞粘附和迁移。研究评估了 suPAR 与心血管疾病 (CVD) 之间的相关性。据推测，suPAR 可能作为 CVD 进展期间炎症激活和负担的指标。 suPAR 升高独立预测急性冠脉综合征、心力衰竭以及冠状动脉疾病和动脉粥样硬化的较差结果。为了指导转化为临床应用，suPAR 已在众多 CVD 环境中进行了评估，以独立或与已确定的传统风险因素结合改善风险辨别。虽然suPAR在肾脏疾病和癌症等其他疾病中的参与已被探索，但只有新的证据表明suPAR在心血管疾病中的机制参与。在这篇综述中，我们介绍了 suPAR 的背景及其作为 CVD 生物标志物的潜在作用。版权所有 © 2024。由 Elsevier Inc. 出版。

Soluble urokinase plasminogen activator receptor (suPAR), the soluble counterpart of urokinase plasminogen activator receptor, is found in the circulation at various levels. suPAR and its parent molecule, cell surface uPAR, exhibit similar structure and extracellular functional roles facilitating fibrinolysis, cellular adhesion, and migration. Studies have assessed the correlation between suPAR in cardiovascular disease (CVD). It is postulated that suPAR may serve as an indicator of inflammatory activation and burden during CVD progression. Increased suPAR independently predicts poorer outcomes in acute coronary syndromes, in heart failure, as well as in coronary artery disease and atherosclerosis. To guide translation into clinical utization, suPAR has been assessed in numerous CVD settings for improved risk discrimination independently or in association with established traditional risk factors. Whilst the involvement of suPAR has been explored in other diseases such as kidney diseases and cancer, there is only emerging evidence of suPAR's mechanistic involvement in cardiovascular disease. In this review, we provide a background into suPAR and its potential role as a biomarker in CVD.Copyright © 2024. Published by Elsevier Inc.